Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Operational Update

7 Jul 2014 07:00

RNS Number : 5184L
Fastnet Oil & Gas PLC
07 July 2014
 



7 July 2014

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

FASTNET IMPROVES TERMS OF AND EXTENDS EXCLUSIVE OPTION AGREEMENT TO FARM INTO THE TENDRARA LAKBIR PETROLEUM AGREEMENT ONSHORE MOROCCO AND PROVIDES OPERATIONAL UPDATE

 

Fastnet (AIM: FAST, ESM: FOI), the UK and Irish listed E&P company focussed on near term exploration and appraisal acreage in Morocco and the Celtic Sea, is pleased to announce that its wholly owned subsidiary Pathfinder Hydrocarbon Ventures Limited ("Pathfinder") has entered into an amended exclusive option agreement with Oil and Gas Investments Funds ("OGIF") (the "Option Agreement"), in relation to eight Exploration Permits comprising the Tendrara Lakbir Petroleum Agreement (the "Tendrara Licence") onshore Morocco.

Following substantive negotiations with its partner OGIF, Fastnet has secured improved commercial terms from those previously announced on 29 May 2013. These include:

· Extension of the Option Agreement to 31 December 2014

· Fastnet's net equity interest increased from 37.5% to 50% upon the option being exercised and subject to the necessary Moroccan Government approvals

· Fastnet will carry OGIF in the first well required during the Initial Period of the Tendrara Licence

· At Fastnet's election, Fastnet will carry OGIF for a well on the TE-5 Structure, or an exploration well on any alternative gas prospect and/or existing gas discovery in the Tendrara Licence Area as required by the committed work programme of the First Extension Period 

· This reduces the drilling commitments under the original Option Agreement, which involved carrying OGIF in three wells; the first well plus two additional appraisal/exploration wells by 1 April 2015 and 1 April 2018, respectively

· The deadline to drill the first well has been extended from 30 September 2014 to 21 April 2015. The time in between exercising the Option Agreement and the drilling deadline allows Fastnet to acquire its net equity interest in the Tendrara Licence and Association Contract prior to commencing the drilling programme as the designated operator 

· Fastnet will be required to provide OGIF with an executed drilling contract or alternatively an irrevocable bank guarantee of USD$2.75 million 

Operational Update

In addition the revised commercial terms under the Option Agreement described above, Fastnet is also pleased to provide the following operational update in relation to the Tendrara Licence:

· Reservoir engineering studies have been completed and currently the new Pre-Stack Seismic Depth Migrations are being interpreted to select final drilling locations and to finalise well design

 

· Well planning, rig selection and environmental impact studies are ongoing and will be completed during this calendar year

 

· In order to accelerate monetisation of the TE-5 gas asset, Fastnet is seeking an additional drilling partner, with onshore gas development experience, to facilitate executing a drilling programme that will target materially higher potential gross gas resources; the gross unrisked High Estimate gas resources for the TE-5 Structure are 891.9 BCF. The Best Estimate gas resources, targeted by the original proposed drilling programme, are 310.5 BCF

 

· Discussions with suitably qualified potential partners, who have all expressed an interest in participating in a potential gas development, are underway and are expected to conclude in H2 2014

Paul Griffiths, Managing Director of Fastnet, commented:

"The revised terms significantly reduce Fastnet's financial exposure and provide us with much improved project economics. The process of bringing in an additional partner is underway. We expect that the new commercial terms and project economics should allow us to attract a major partner, with experience in developing and monetising onshore gas discoveries, by offering sufficient equity, whilst maintaining a material equity level for Fastnet shareholders as we seek to target materially higher potential gas resources in the planned drilling programme. We maintain our strategy of prudently managing our cash resources as we did through our successful Foum Assaka farm-out, which de-risked our financial exposure to the drilling costs. We believe that the Tendrara Licence is highly attractive to a potential strategic gas partner given the existing TE-5 gas discovery with near term development potential, and the additional prospectivity of multiple play types within the large licence area which provides significant potential upside."

For further information, please contact:

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Paul Griffiths, Managing Director

+353 (1) 644 0007

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

 

GMP Securities Europe LLP

(Joint Broker)

Rob Collins, Emily Morris, Liz Williamson

 

+44 (20) 20 7467 2800

Davy

(ESM Adviser & Joint Broker)

John Frain

Anthony Farrell

 

 +353 (1) 679 6363

Bell Pottinger

Philip Dennis, Rollo Crichton-Stuart, Jimmy Lea

 

 +44 (0) 207 861 3232

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFZLFBZDFEBBV
Date   Source Headline
4th Mar 202112:00 pmRNSAmryt Announces Record FY 2020 Results
25th Feb 20217:00 amRNSAmryt Supports Global Rare Disease Day 2021
24th Feb 20217:00 amGNWAmryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
10th Feb 20217:00 amRNSAmryt to Present at SVB Leerink Conference
4th Feb 20217:00 amGNWAmryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
20th Jan 20217:00 amGNWAmryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6th Jan 20217:00 amRNSAmryt to present at H.C Wainwright Conference
23rd Dec 20207:00 amGNWAmryt Granted Orphan Drug Designation by the FDA for AP103
17th Dec 20207:00 amGNWAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11th Dec 202010:00 amGNWHolding(s) in Company
9th Dec 20202:45 pmGNWHolding(s) in Company
9th Dec 20207:00 amGNWAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
8th Dec 20207:00 amGNWAmryt Announces $40m Private Placement with Leading Biotech Investors
5th Nov 202012:00 pmGNWAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
29th Oct 20207:00 amGNWAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
19th Oct 20207:00 amGNWAmryt and Swixx Sign Distribution Deal for Lojuxta
14th Oct 20207:00 amRNSAMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020
14th Oct 20207:00 amGNWNotice of Results
12th Oct 202011:00 amGNWHolding(s) in Company
9th Oct 20207:00 amGNWVirtual Analyst & Investor Event - Tuesday November 3, 2020
8th Oct 20207:00 amGNWAMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020
1st Oct 20207:00 amGNWExercise of Options and Total Voting Rights
30th Sep 202012:30 pmGNWHolding(s) in Company
23rd Sep 20207:00 amRNSAMRYT SUPPORTS GLOBAL FH AWARENESS DAY
21st Sep 202011:00 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
15th Sep 20207:00 amRNSPOSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION
9th Sep 20202:05 pmRNSSecond Price Monitoring Extn
9th Sep 20202:00 pmRNSPrice Monitoring Extension
9th Sep 20207:00 amRNSPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
11th Aug 202011:09 amRNSCANCELLATION OF ADMISSION TO EURONEXT GROWTH
7th Aug 20207:00 amRNSAMRYT PRESENTING AT CANACCORD GENUITY CONFERENCE
6th Aug 202012:00 pmRNSAMRYT ANNOUNCES Q2 2020 RESULTS
29th Jul 20202:30 pmRNSResult of AGM
29th Jul 20207:00 amRNSAMRYT HOSTING KOL CALL ON EB DISEASE LANDSCAPE
20th Jul 20207:00 amRNSAMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
15th Jul 20208:00 amRNSEuronext Growth Dublin Notice
10th Jul 20207:00 amRNSExercise of Warrants & Issue of Ordinary Shares
8th Jul 20203:09 pmRNSAMRYT LISTED ON NASDAQ & CEO TO RING CLOSING BELL
30th Jun 20207:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
24th Jun 20207:00 amRNSForm F-1 publicly filed for impending US listing
4th Jun 20202:20 pmRNSDirector/PDMR Shareholding
3rd Jun 202011:30 amRNSDirector/PDMR Shareholding
3rd Jun 20207:00 amRNSAMRYT & SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA
11th May 20207:00 amRNSQ1 2020 RESULTS
11th May 20207:00 amRNSFY 2019 RESULTS
7th May 20209:00 amRNSNotice of Results
7th May 20207:00 amRNSFILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101
23rd Apr 20207:00 amRNSEASE CLINICAL STUDY UPDATE
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20207:00 amRNSMarket Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.